Literature DB >> 25443003

Predictors of mortality after surgical management of lung cancer in the National Cancer Database.

Joshua E Rosen1, Jacquelyn G Hancock1, Anthony W Kim1, Frank C Detterbeck1, Daniel J Boffa2.   

Abstract

BACKGROUND: Surgical resection represents the standard of care for locoregionally confined non-small cell lung cancer (NSCLC); however, surgical complications may compromise the overall outcome. Adverse events after lung cancer surgery have been studied extensively, yet available databases have significant limitations (with respect to size, provider, patient age, and so forth). The National Cancer Database (NCDB) is the largest cancer registry in the world, capturing 67% of newly diagnosed NSCLC in the United States. We studied surgically managed NSCLC patients in the NCDB to more accurately assess factors that influence perioperative outcomes.
METHODS: Patients diagnosed with NSCLC from 2004 to 2009 in the NCDB who were managed with surgical resection were included (n = 119,146). Primary endpoints included death within 30 days of surgery and extended length of stay (more than 14 days).
RESULTS: Overall 30-day mortality rate was 3.4% and varied by procedure: lobectomy/bilobectomy (2.6%), wedge resection (4.2%), extended lobectomy/bilobectomy (4%), and pneumonectomy (8.5%). By multivariable analysis, increasing age, male sex, increasing comorbidities, and decreased facility volume were associated with higher 30-day mortality. Of patients who underwent lobectomy, 9.1% had an extended length of stay. On multivariable analysis, increasing age, male sex, increasing comorbidities, decreasing facility volume, and right-sided tumors were associated with increased incidence of extended length of stay.
CONCLUSIONS: Adverse events after the surgical treatment of NSCLC in the NCDB occur with a similar frequency and are predicted by similar patient, procedural, and facility variables as have been identified by more restricted data resources. The NCDB appears to be a valuable resource to study NSCLC in the United States.
Copyright © 2014 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 25443003     DOI: 10.1016/j.athoracsur.2014.07.007

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  26 in total

Review 1.  Postlobectomy Early Complications.

Authors:  Elena Ziarnik; Eric L Grogan
Journal:  Thorac Surg Clin       Date:  2015-06-12       Impact factor: 1.750

2.  Inequivalence of non-aggressiveness in clinically diagnosed lung cancers and overdiagnosis in lung cancer screening trials.

Authors:  Jerome M Reich; Jong S Kim
Journal:  J Thorac Dis       Date:  2018-03       Impact factor: 2.895

3.  Characterizing trends in treatment modalities for localized muscle-invasive bladder cancer in the pre-immunotherapy era.

Authors:  Sean A Fletcher; Sabrina S Harmouch; Marieke J Krimphove; Alexander P Cole; Sebastian Berg; Philipp Gild; Mark A Preston; Guru P Sonpavde; Adam S Kibel; Maxine Sun; Toni K Choueiri; Quoc-Dien Trinh
Journal:  World J Urol       Date:  2018-06-14       Impact factor: 4.226

4.  Socioeconomic Factors Are Associated With Readmission After Lobectomy for Early Stage Lung Cancer.

Authors:  Rachel L Medbery; Theresa W Gillespie; Yuan Liu; Dana C Nickleach; Joseph Lipscomb; Manu S Sancheti; Allan Pickens; Seth D Force; Felix G Fernandez
Journal:  Ann Thorac Surg       Date:  2016-07-29       Impact factor: 4.330

5.  Neighborly Help or Itinerant Surgery?

Authors:  James S Allan; Alberto Ferreres; Robert M Sade
Journal:  Ann Thorac Surg       Date:  2018-10-10       Impact factor: 4.330

6.  Perioperative mortality and morbidity after sublobar versus lobar resection for early-stage non-small-cell lung cancer: post-hoc analysis of an international, randomised, phase 3 trial (CALGB/Alliance 140503).

Authors:  Nasser K Altorki; Xiaofei Wang; Dennis Wigle; Lin Gu; Gail Darling; Ahmad S Ashrafi; Rodney Landrenau; Daniel Miller; Moishe Liberman; David R Jones; Robert Keenan; Massimo Conti; Gavin Wright; Linda J Veit; Suresh S Ramalingam; Mohamed Kamel; Harvey I Pass; John D Mitchell; Thomas Stinchcombe; Everett Vokes; Leslie J Kohman
Journal:  Lancet Respir Med       Date:  2018-11-12       Impact factor: 30.700

7.  Five reasons for caution in advocating low-dose computerized tomographic lung cancer screening.

Authors:  Jerome M Reich; Jong S Kim
Journal:  J Thorac Dis       Date:  2017-09       Impact factor: 2.895

8.  Survival rate and prognostic factors of surgically resected clinically synchronous multiple primary non-small cell lung cancer and further differentiation from intrapulmonary metastasis.

Authors:  Fei Xiao; Deruo Liu; Yongqing Guo; Bin Shi; Zhiyi Song; Yanchu Tian; Zhenrong Zhang; Chaoyang Liang
Journal:  J Thorac Dis       Date:  2017-04       Impact factor: 2.895

9.  Surgically Managed Clinical Stage IIIA-Clinical N2 Lung Cancer in The Society of Thoracic Surgeons Database.

Authors:  Daniel Boffa; Felix G Fernandez; Sunghee Kim; Andrzej Kosinski; Mark W Onaitis; Patricia Cowper; Jeffrey P Jacobs; Cameron D Wright; Joe B Putnam; Anthony P Furnary
Journal:  Ann Thorac Surg       Date:  2017-05-17       Impact factor: 4.330

10.  Patient-Reported Symptom Interference as a Measure of Postsurgery Functional Recovery in Lung Cancer.

Authors:  Qiuling Shi; Xin Shelley Wang; Ara A Vaporciyan; David C Rice; Keyuri U Popat; Charles S Cleeland
Journal:  J Pain Symptom Manage       Date:  2016-08-10       Impact factor: 3.612

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.